Rocket Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDRocket Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 53), indicating performance broadly in line with the market. Earnings growth of 25% provides fundamental context to the price action. However, price is extended 25% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.22 | +26.28% | ABOVE |
| 50 SMA | $3.26 | +24.98% | ABOVE |
| 100 SMA | $3.68 | +10.69% | ABOVE |
| 150 SMA | $3.61 | +12.63% | ABOVE |
| 200 SMA | $3.56 | +14.33% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RCKT in an uptrend right now?
RCKT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RCKT overbought or oversold?
RCKT's RSI (14) is 74. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RCKT outperforming the market?
RCKT has a Relative Strength (RS) Rating of 53 out of 99. RCKT is performing about average compared to the market.
Where is RCKT in its 52-week range?
RCKT is trading at $4.07, which is 75% of its 52-week high ($5.45) and 53% above its 52-week low ($2.53).
How volatile is RCKT?
RCKT has a Beta of 1.89 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.